ResMed
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Option
SMITH ADRIAN M officer: COO Europe
ResMed Options 10,000 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Comon Stock 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 8,200 N/A N/A
Option
FARRELL PETER C director
ResMed Options 6,200 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Option
FARRELL PETER C director
ResMed Options 6,174 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 8,174 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 6,174 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
ROBERTS CHRISTOPHER G other: Retired Director
ResMed Common Stock 18,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 8,200 N/A N/A
Option
FARRELL PETER C director
ResMed Options 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 4,000 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 12,400 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 8,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 8,200 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock 6,200 N/A N/A
Option
FARRELL PETER C director
ResMed Common Stock (Options) 6,200 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Option
MCCARTHY DONAGH director
Resmed Common Stock 14,000 N/A N/A
Sale
MCCARTHY DONAGH director
Resmed Common Stock 14,000 N/A N/A
Option
MCCARTHY DONAGH director
Resmed Common Stock 14,000 N/A N/A
Sale
ROBERTS CHRISTOPHER G other: Retired Director
ResMed Common Stock 30,000 N/A N/A
Sale
QUINN MICHAEL A director
ResMed Common Stock 3,000 N/A N/A
Option
SHINDHELM KLAUS H officer: Sr. Vice President, Op..
ResMed Common Stock 3,800 N/A N/A
Sale
SHINDHELM KLAUS H officer: Sr. Vice President, Op..
ResMed Common Stock 3,800 N/A N/A
Sale
FARRELL PETER C director
ResMed Common Stock 2,000 N/A N/A
Option
SHINDHELM KLAUS H officer: Sr. Vice President, Op..
ResMed Common Stock 3,800 N/A N/A
Sale
QUINN MICHAEL A director
Resmed Common Stock 5,000 N/A N/A
Sale
PACE GARY W other: Retired director
ResMed Common Stock 7,000 N/A N/A
Option
FLICKER WALTER officer: VP, Assist. Corp. Secr..
ResMed Common Stock 2,000 N/A N/A

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.